Everolimus+in+de+novo+liver+transplant+recipients-a+systematic+review.pdfVIP

Everolimus in LT Meta-Analysis Everolimus in de novo liver transplant recipients: a systematic review Cheng-Yong Tang, Ai Shen, Xu-Fu Wei, Qing-Dong Li, Rui Liu, He-Jun Deng, Yong-Zhong Wu and Zhong-Jun Wu Chongqing, China BACKGROUND: Everolimus has no nephrotoxicity and is creased tBPAR (RR: 1.71; 95% CI: 1.15-2.53; P0.01). Everolimus used to treat patients with post-liver transplant chronic renal decreased the risk of neoplasms/tumor recurrence after liver insufficiency. The present systematic review was to eval